21 December 2020 - license agreement
The AIM-listed developer of cancer therapies and diagnostics has entered into a licence agreement with Astrea Bioseparations for the latter to use Avacta's proprietary affimer technology. This will lead to an upfront payment of £0.5m to Avacta, whilst Avacta will also receive royalties on future sales of Astrea products containing affimer reagents. This is clearly a strong endorsement of the company's affimer technology. The share price of the company has drifted back to its lowest level in six months and we therefore rate the shares as a BUY
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
